Transformation of trans-4-Aryl-3-chloro-1-(2-chloroethyl)azetidin-2-ones into 3-Aryl-2-(ethylamino)propan-1-ols via Intermediate 1-(1-Aryl-2-chloro-3-hydroxypropyl)aziridines and trans-2-Aryl-3-(hydroxymethyl)aziridines
摘要:
trans-4-Aryl-3-chloro-1-(2-chloroethyl)azetidin-2-ones, prepared through cyclocondensation of chloroketene and the appropriate imines in a diastereoselective way, were unexpectedly transformed into 3-aryl-2-(ethylamino)propan-1-ols using LiAlH4 in THF under reflux. A stepwise analysis showed that the initially formed 1-(1-aryl-2-chloro-3-hydroxypropyl)aziridines were converted into trans-2-aryl-3-(hydroxymethyl)aziridines, most probably via N-spiro bis-aziridinium intermediates, which were subsequently prone to undergo ring opening by LiAlH4 to afford 3-aryl-2-(ethylamino)propan-1-ols.
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
1
本文描述了作为大麻素受体配体的化合物(I)及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
Amino acids and peptides. IV. Selective reduction of peptide-ester groups
作者:Osamu Yonemitsu、Tatsuo Hamada、Yuichi Kanaoka
DOI:10.1016/s0040-4039(00)75503-1
日期:1968.1
1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer.
申请人:Bristol-Myers Squibb Company
公开号:EP2861581B1
公开(公告)日:2017-02-01
US7268133B2
申请人:——
公开号:US7268133B2
公开(公告)日:2007-09-11
Yonemitsu,O. et al., Chemical and pharmaceutical bulletin, 1969, vol. 17, p. 2075 - 2082